Epetraborole

Synonym(s): AN3365  |  GSK 2251052  |  GSK2251052

Class: Aminoacyl-tRNA synthetase inhibitor (boron-heterocyclic leucyl-tRNA synthetase [LeuRS] inhibitor)

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Inhibits leucyl-tRNA synthetase (LeuRS) blocking protein synthesis, active against Enterobacteriaceae, Peudomonas aeruginosa and Mycobacterium abscessus
Combined with other compounds:	Yes
Description:	Synthetic compound. Rapid emergence of resistance; developed in combination for nontuberculous mycobacterium infections
Institute where first reported:	AN2 Therapeutics (Anacor, GSK)
Year first mentioned:	2013
Highest developmental phase:	Phase 2
Development status:	Inactive (as of 2023
Reason Dropped:	Phase 2 trial terminated due to resistance concerns

Chemical structure(s):
Canonical SMILES:	C1=CC(=C2C(=C1)[C@@H](CN)OB2O)OCCCO
Isomeric SMILES:	B1(C2=C(C=CC=C2OCCCO)[C@H](O1)CN)O
InChI:	InChI=1S/C11H16BNO4/c13-7-10-8-3-1-4-9(16-6-2-5-14)11(8)12(15)17-10/h1,3-4,10,14-15H,2,5-7,13H2/t10-/m1/s1
InChI Key:	FXQIIDINBDJDKL-SNVBAGLBSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/46836890

External links:
Guide to Pharmacology:	epetraborole
Main Source:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3591879/
Citation:	https://journals.asm.org/doi/10.1128/AAC.01156-21